Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a major managed Medicare agreement for TONMYA (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective Jan. 1, 2027. Combined with previously announced commercial coverage agreements and broad Medicaid availability, the company said TONMYA will have pharmacy coverage reaching approximately 145 million covered lives, or 46% of the U.S. covered market, while discussions with additional commercial and Medicare payers continue.
Following the expanded coverage and positive launch metrics, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company said it is also expanding marketing and medical affairs initiatives to increase awareness of TONMYA as a first-in-class, non-opioid treatment option for fibromyalgia.
This expansion is significant for leaders in business and technology, as it demonstrates how a biotechnology company can leverage strategic payer agreements to scale access to a novel therapy. For the healthcare industry, the move highlights the growing emphasis on non-opioid pain management alternatives, which aligns with regulatory and societal pressures to reduce opioid dependence. The coverage of 145 million lives—nearly half the U.S. insured market—positions TONMYA as a potential standard of care for fibromyalgia, a condition affecting an estimated 4 million adults in the United States.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The implications of this coverage expansion extend beyond Tonix. For patients, broader access to a non-opioid therapy could improve quality of life and reduce reliance on medications with abuse potential. For investors, the expansion signals strong commercial execution and potential revenue growth. The planned sales force increase underscores Tonix’s confidence in TONMYA’s market adoption. As the company continues discussions with other payers, further coverage gains could solidify TONMYA’s position in the fibromyalgia treatment landscape.
Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
